You are here

Article Text

Article menu
Download PDFPDF
Letter
Crohn’s-like enterocolitis associated with mycophenolic acid treatment
  1. D Dost1,
  2. M E van Leerdam2,
  3. H van Dekken3,
  4. W Weimar4,
  5. E J Kuipers2,4,
  6. A H Bijl5,
  7. T van Gelder1,4
  1. 1
    Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
  2. 2
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
  3. 3
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
  4. 4
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
  5. 5
    Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, The Netherlands
  1. Dr T van Gelder, Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands; t.vangelder{at}erasmusmc.nl

http://dx.doi.org/10.1136/gut.2007.139972

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In the European Crohn's and Colitis Organisation (ECCO) paper of 2006 (Gut 2006;55(Suppl 1):i1–15), consensus on the diagnosis of Crohn’s disease was described. However, we were surprised that nothing was mentioned about the association between the use of mycophenolate mofetil (MMF, Cellcept) and the occurrence of Crohn’s-like enterocolitis.

    MMF is widely used to prevent rejection after solid organ transplantation. The active compound, mycophenolic acid (MPA), is a reversible, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo purine biosynthesis in T and B lymphocytes. The most common adverse drug reactions of MMF are gastro-intestinal complaints.1–3 In 2003, a prospective cohort study including 26 renal transplant recipients with persistent diarrhoea showed for the first time that in patients using MMF, Crohn’s-like enterocolitis could …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Patient consent: Obtained.